HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Murine host responses to respiratory syncytial virus (RSV) following intranasal administration of a Protollin-adjuvanted, epitope-enhanced recombinant G protein vaccine.

AbstractBACKGROUND:
Immunization of mice with the G protein of respiratory syncytial virus (RSV) characteristically induces an immune response that is partially protective, but which can prime for pulmonary eosinophilia. We have shown previously that the N191A mutation in a recombinant RSV G protein fragment is associated with reduced pulmonary eosinophilic infiltration when administered with alum subcutaneously in BALB/c mice followed by RSV challenge. We hypothesize that the performance of this "epitope enhanced" recombinant G protein fragment may be further improved by combining with the newly developed adjuvant, Protollin, coupled with intranasal delivery.
OBJECTIVES:
To investigate efficacy of an intranasally delivered, Protollin-adjuvanted, epitope-enhanced recombinant G protein vaccine in BALB/c mice.
STUDY DESIGN:
Recombinant protein, designated Trx-G128-229, consisted of a bacterially expressed central fragment (amino acids 128-229) of the RSV Long strain G protein fused to a fragment of thioredoxin (Trx). BALB/c mice were chosen to evaluate the effectiveness of wild type and epitope-enhanced Trx-G128-229 as a nasal vaccine with the adjuvant Protollin.
RESULTS:
The intranasal administration of Trx-G128-229 with Protollin conferred similar protection against RSV challenge as subcutaneously administered Trx-G128-229 with alum, but with markedly reduced eosinophilia and the Th2 cytokine IL-13.
CONCLUSIONS:
These results support the concept of an RSV vaccine optimized by combined strategies, including epitope enhancement and judicious selection of adjuvants.
AuthorsYan Huang, Sonya L Cyr, David S Burt, Robert Anderson
JournalJournal of clinical virology : the official publication of the Pan American Society for Clinical Virology (J Clin Virol) Vol. 44 Issue 4 Pg. 287-91 (Apr 2009) ISSN: 1873-5967 [Electronic] Netherlands
PMID19233722 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Adjuvants, Immunologic
  • Antibodies, Viral
  • Drug Combinations
  • Immunoglobulin G
  • Lipopolysaccharides
  • Protollin
  • Respiratory Syncytial Virus Vaccines
  • Vaccines, Subunit
  • Vaccines, Synthetic
  • Viral Envelope Proteins
  • attachment protein G
  • Cysteine Endopeptidases
Topics
  • Adjuvants, Immunologic (administration & dosage, pharmacology)
  • Administration, Intranasal
  • Animals
  • Antibodies, Viral (blood)
  • Cysteine Endopeptidases (administration & dosage, pharmacology)
  • Drug Combinations
  • Eosinophilia (prevention & control)
  • Female
  • Immunoglobulin G (blood)
  • Lipopolysaccharides (administration & dosage, pharmacology)
  • Lung (virology)
  • Mice
  • Mice, Inbred BALB C
  • Respiratory Syncytial Virus Infections (prevention & control)
  • Respiratory Syncytial Virus Vaccines (administration & dosage, genetics, immunology)
  • Respiratory Syncytial Viruses (genetics, immunology)
  • Vaccines, Subunit (administration & dosage, genetics, immunology)
  • Vaccines, Synthetic (administration & dosage, genetics, immunology)
  • Viral Envelope Proteins (administration & dosage, genetics, immunology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: